biote (BTMD)
NASDAQ:BTMD
Want to see BTMD full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Not Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.02Last Year’s EPS
0.1Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: material short-term financial impacts in Q1 driven by a voluntary product recall and associated supply constraints materially reduced revenue, margins and net income. Offsetting these headwinds were notable operational and commercial progress — strong dietary supplement growth (+19.1%), a sizable expansion of the salesforce (to ~120 reps), training of 200+ new practitioners (+16.5% YoY), active remediation at Asteria (second shift and safety stock build), and maintained full-year guidance (revenue > $190M; adjusted EBITDA > $38M). Management expressed confidence that the issues are temporary and expected a return to procedure revenue growth in the second half of 2026, but acknowledged near-term persisting effects into Q2.Company Guidance
Dietary Supplement Revenue Growth
Dietary supplement revenue grew 19.1% year-over-year to $11.0 million in Q1 2026, driven largely by continued strength in the e-commerce channel; company expects dietary supplement revenue to grow at a mid- to high-single-digit rate for full-year 2026.
Salesforce Expansion
Commercial organization expanded from over 90 reps at the end of 2025 to approximately 120 reps in 2026, with more than 25 new hires in Q1, intended to increase sales capacity and support future practitioner network growth.
Practitioner Training Increase
Trained more than 200 new practitioners in Q1, a 16.5% increase versus Q1 2025; management cited new practitioner onboarding as a leading indicator for future procedure and supplement sales (typical ~6 months to meaningful contribution).
Maintained Full-Year Guidance
Company maintained 2026 guidance of revenue above $190 million and adjusted EBITDA greater than $38 million despite the temporary Q1 headwind from the voluntary recall.
Operational Remediation Underway
Asteria Health added a second production shift and other measures to scale output; management expects to fully restore Asteria supply continuity by the end of Q2 2026 and to rebuild safety stock, while continuing to use third-party partners to fulfill near-term demand.
Limited Clinic Attrition
Management reported attrition has stabilized and noted no meaningful uptick in clinic attrition attributable to the recall; anecdotal signs of daily volume improvement prior to the recall were observed.
Balance Sheet Action and Operating Cash
Operating cash flow was $3.9 million in Q1 and cash and cash equivalents were $5.3 million as of March 31, 2026; company fully repaid the remaining amount under its share repurchase liabilities in January 2026.
BTMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BTMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $2.20 | $2.09 | -5.00% |
Mar 11, 2026 | $1.72 | $1.54 | -10.47% |
Nov 05, 2025 | $2.93 | $2.84 | -3.07% |
Aug 06, 2025 | $3.86 | $2.92 | -24.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does biote (BTMD) report earnings?
biote (BTMD) is schdueled to report earning on Aug 06, 2026, After Close (Not Confirmed).
What is biote (BTMD) earnings time?
biote (BTMD) earnings time is at Aug 06, 2026, After Close (Not Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BTMD EPS forecast?
BTMD EPS forecast for the fiscal quarter 2026 (Q2) is 0.02.